Nuvalent Doses First Subject in Phase Ia/Ib Trial of Lung Cancer Treatment
Express News | Nuvalent Begins Phase 1 Trial for New HER2-Selective Lung Cancer Treatment
Express News | Nuvalent Announces First Patient Dosed in Heroex-1 Phase 1a/1B Clinical Trial of Nvl-330, Its Novel Her2-Selective Inhibitor
Nuvalent Insider Sold Shares Worth $403,621, According to a Recent SEC Filing
Express News | Nuvalent To Present Updated Data From ARROS-1 Phase 1/2 Clinical Trial Of Zidesamtinib And ALKOVE-1 Phase 1/2 Clinical Trial Of NVL-655 at ESMO Congress 2024
Express News | Nuvalent Announces Promotion of Henry Pelish, Ph.d. to Chief Scientific Officer
Nuvalent(NUVL.US) Officer Sells US$219.69K in Common Stock
Nuvalent Is Maintained at Buy by Stifel
Stifel Maintains Nuvalent(NUVL.US) With Buy Rating, Raises Target Price to $115
Express News | Nuvalent Inc : Stifel Raises Target Price to $115 From $103
Nuvalent(NUVL.US) Officer Sells US$377.7K in Common Stock
Nuvalent(NUVL.US) Officer Sells US$754.34K in Common Stock
Nuvalent(NUVL.US) Director Sells US$160.44K in Common Stock
Nuvalent(NUVL.US) Director Sells US$387.78K in Common Stock
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
Nuvalent(NUVL.US) Officer Sells US$643.21K in Common Stock
Nuvalent Insider Sold Shares Worth $643,213, According to a Recent SEC Filing
Nuvalent(NUVL.US) Director Sells US$134.44K in Common Stock
Nuvalent to Participate in the 2024 Jefferies Global Healthcare Conference
Nuvalent(NUVL.US) Director Sells US$345.45K in Common Stock